Citi analyst David Lebowitz has maintained a Buy rating on BridgeBio Pharma (BBIO) with a price target of $45.00, following promising developments within the company. The initial sales data for BridgeBio's drug, Attruby (acoramidis), has shown a robust market entry, with 430 prescriptions written by 248 doctors just seven weeks after its approval. This early success indicates a strong potential for future revenue growth.
BridgeBio's pipeline is also progressing well, with all three of its pivotal Phase 3 trials fully enrolled and results expected in the second half of 2025. Lebowitz emphasizes the strategic timing of these developments, as investors are likely to focus on Attruby’s launch details in the upcoming earnings report. Additionally, the potential approval of Alnylam’s competing drug, Amvuttra, in March introduces a competitive dynamic to the market landscape.
These factors, combined with a projected 54.7% return on the stock, underpin Lebowitz's optimistic Buy recommendation for BridgeBio Pharma. According to TipRanks, Lebowitz is a 3-star analyst with an average return of 1.6% and a 51.09% success rate, covering the Healthcare sector with a focus on stocks such as Exelixis, BridgeBio Pharma, and BioMarin Pharmaceutical.
BridgeBio Pharma, Inc. is engaged in developing transformative medicines to treat patients suffering from mendelian diseases. Its pipeline includes 15 development programs, ranging from early discovery to late-stage development. The company was founded on May 17, 2019, and is headquartered in Palo Alto, CA.
